Rodrigo Perez Pereira

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2020 · 650 citations

Pharmacy, Oncology, Pharmacotherapy +15

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Paolo A. Ascierto, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet Oncology · 2022 · 104 citations

Pharmacy, Oncology, Pharmacotherapy +14

Factors associated with uncontrolled asthma in Porto Alegre, Brazil

Paulo de Tarso Roth Dalcin, Diego Millán Menegotto, Angela Zanonato et al. · Brazilian Journal of Medical and Biological Research · 2009 · 31 citations · Full text

Medicine, Internal Medicine, Clinical Pharmacology +12

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma

Caroline Robert, Karl D. Lewis, Ralf Gutzmer et al. · Annals of Oncology · 2022 · 28 citations · Full text

Medicine, Oncology, Pharmacology +17

Masticatory efficiency in complete denture and single implant-retained mandibular overdenture wearers with different occlusion schemes: A randomized clinical trial

Cibele O.M. Rocha, Diogo Longhini, Rodrigo Perez Pereira et al. · Journal of Prosthetic Dentistry · 2021 · 14 citations · Full text

Dentistry, Implant Dentistry, Prosthodontic Treatment Planning +14